Skip to content
Announcement:

Latest Publication: Read our teams’ latest paper in Antibiotics, showing reduced nephrotoxicity of a novel formulation of polymyxin B compared to the clinical formulation using a validated primary human proximal tubule cell model.

Updates - Page 4

An experiment being carried out
13th April, 2021

NB collaborates with Takeda Pharmaceuticals on renal drug safety evaluation study

Newcells Biotech and Takeda Pharmaceutical International Co. have collaborated in a study designed to assess drug safety. The study evaluated a set of 36 known drugs and…

Read update
3d lung airway model
30th March, 2021

Successful EU initiative adds a new 3D lung airway model to NB’s portfolio for drug safety testing

Newcells Biotech is collaborating with industry leaders and expert academics in a European-wide interdisciplinary initiative to develop animal-free methods for drug safety evaluations. The initiative (the EU funded 

Read update
Two mice
25th February, 2021

Our commitment to the 3Rs

There are few topics more controversial than the use of animals in science, despite the enormous contribution animal experimentation continues to make to the development of new medicines and…

Read update
Newcells Secure Investment
23rd February, 2021

Newcells Biotech secures over £5m for 3D tissue models

Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25m worth of funding to accelerate their growth plans in the international life sciences market.The funding…

Read update
Developing a 3D in vitro proximal tubule model for chronic toxicity studies
26th January, 2021

Developing a 3D in vitro proximal tubule model for chronic toxicity studies

The kidney proximal tubule is of key interest in drug discovery. This is due to its primary role in the excretion and reabsorption of xenobiotics, such as drugs and…

Read update
Covid 19 Update Banner
13th January, 2021

Covid-19 action plan – 2021 update

In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and…

Read update
Newcells Biotech aProximate Model
14th December, 2020

Improved in vitro renal tubular drug transport modelling to meet regulatory & development cost challenges

The proximal tubule is key due to its role in the excretion and reabsorption of many xenobiotic compounds. Due to the high costs associated with drug discovery and the…

Read update
Drug Target Review
3rd December, 2020

Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection

Covid-19 is known to infect the lungs. However, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, we…

Read update
Structure of the newcells retinal model
27th October, 2020

Diagnosing unresolved Stargardt disease using retina-specific splicing isoforms obtained from retinal organoids

At Newcells Biotech, we specialise in the large-scale production of retinal organoids for the purpose of in vitro toxicology efficacy studies and disease modelling. Our differentiation protocols generate organoids which…

Read update
Development of functioning in vitro lung assay for modelling Covid-19 infection
31st July, 2020

Development of functioning in vitro lung assay for modelling Covid-19 infection

Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform…

Read update
Newcells scales up its operations in the biosphere
26th June, 2020

Newcells scales up its operations in The Biosphere

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory 

Read update
An image of a needle being readied to administer a vaccine
11th June, 2020

An overview of vaccine development & sub-types

Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have 

Read update

Get our latest updates straight to your inbox